Following Johnson & Johnson’s $158 million resolution with Texas several states have demanded higher payments, leading the U.S. Justice Department to raise its demand to $1.8 billion to settle its claims of false and misleading marketing. Risperdal was initially approved for psychotic disorders, but J&J marketed it for bipolar disorder, dementia, mood and anxiety disorders and other unapproved uses. Other states have indicated potential interest in litigation as well.
